Serous Ovarian Cancer

This study identified a novel gene expression signature predictive of bevacizumab response in ovarian cancer patients. Utilizing machine learning approaches on RNA-seq and microarray data, researchers discovered a signature associated with significantly improved overall survival in patients receiving bevacizumab. This signature, potentially linked to stemness-like features and the CTCFL gene, was validated across multiple independent cohorts. These findings suggest transcriptional heterogeneity in ovarian cancer beyond current classifications, offering a pathway for improved patient selection.

This nationwide Japanese study resolved the status of the BRCA2 c.7847C>T (p.Ser2616Phe) variant, which is specific to the Japanese population and was previously of uncertain significance. By integrating quantitative cosegregation analyses, robust functional evidence, and population frequency data, researchers accumulated strong evidence. The evaluation led to the reclassification of this variant as "Pathogenic" according to the ClinGen ENIGMA framework. This reclassification is crucial for ensuring eligible Japanese patients gain access to appropriate targeted therapies, such as PARP inhibitors.